profit from every $100 of sales.
$0$100
Burning Rock Biotech
$13.33+0.68% today
+9.2% in 1 year
1-year low $7.041-year high $41.06
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Burning Rock Biotech sold, what it kept, and what it did with the cash.
Sales went from CN¥563 million in 2022 to CN¥540 million in 2025, with -CN¥55.3 million of profit last year.
SalesProfit
Burning Rock Biotech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Burning Rock Biotech | No profit yet | ||
 Illumina | 37.3× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Burning Rock Biotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 563 | 537 | 516 | 540 | |
| 380 | 363 | 362 | 403 | |
| -980 | -669 | -322 | -55 | |
| -856 | -518 | -289 | -32 | |
| -971 | -654 | -347 | -55 | |
| -93.50 | -63.80 | -33.70 | -5.20 | |
| 67.5% | 67.6% | 70.3% | 74.7% | |
| -174.1% | -124.5% | -62.5% | -10.2% | |
| -172.4% | -121.6% | -67.2% | -10.3% |
Balance sheet
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,587 | 1,040 | 885 | 820 |
| Cash | 905 | 615 | 520 | 478 |
| Total debt | 51 | 12 | 52 | 43 |
| Total liabilities | 429 | 272 | 304 | 285 |
| 1,158 | 768 | 581 | 535 | |
| 10 | 10 | 10 | 11 | |
| -64.1% | -65.9% | -42.5% | -7.3% | |
| -83.8% | -85.1% | -59.7% | -10.3% |
Cash flow
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -457 | -256 | -92 | -28 | |
| 70 | 9 | 6 | 5 | |
| -527 | -265 | -98 | -34 | |
| Dividends paid | – | – | – | – |
| 72 | 7 | 0 | 0 | |
| 327 | 261 | 156 | 14 |
Valuation
- –
- –
- –
- 0.2×
- 1.7×
- –
- –
- -3.6%
- -5.9%
- 0.0%
Profitability
- 74.7%
- -10.2%
- -10.3%
- -4.9%
- -9.3%
- -53.9%
- -9.9%
- -6.7%
- -9.5%
- 30.9%
Growth
- −1.4%
- –
- +65.7%
- –
- −43.3%
Financial health
- -13.6×
- 0.08
- 5.3%
- -3,696.5×
- 2.99
- 2.76
- 0.66
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 27%of 952
Bottom 15%of 883
Bottom 13%of 870
Bottom 22%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 12, 2026 | -0.21 | -1.40 | +85.0% |
| Nov 20, 2025 | -0.26 | – | – |
| Sep 8, 2025 | -0.15 | – | – |
| Jun 6, 2025 | -0.17 | – | – |
| Mar 25, 2025 | -1.08 | -1.40 | +22.7% |
| Dec 3, 2024 | -0.50 | -1.41 | +64.5% |
| Aug 22, 2024 | -0.14 | -1.49 | +90.6% |
| May 29, 2024 | -0.16 | -1.52 | +89.5% |
News
AI Is Burning Through More Money Than Any Technology Boom in History — Now Comes the Hard PartYahoo Finance · Oct 4, 2026‘My main goal is to help people’: I’m single, 74, with $10 million burning a hole in my pocket. What should I do?MarketWatch · Sep 20, 2026Goodyear burning rubber and cash as turnaround plan continuesCNBC · Aug 29, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
73Pass
Philip Fisher
43No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
43No pass
Terry Smith
32No pass
Questions about Burning Rock Biotech
Is Burning Rock Biotech a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Burning Rock Biotech AI analysis
What does Burning Rock Biotech do?
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. It is in Medical - Diagnostics & Research.
Does Burning Rock Biotech pay a dividend?
No. Burning Rock Biotech does not pay a dividend at the moment.
Is Burning Rock Biotech stock halal?
No. Burning Rock Biotech does not pass our halal screen: its cash and confirmed interest-bearing investments are 51% of its market value, at or above the 33% limit. How we check
How has Burning Rock Biotech stock done over the past year?
Up 9.2% over the past twelve months, to $13.33. It traded between $7.04 and $41.06 and is 67.5% below its high.
Who are Burning Rock Biotech's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Burning Rock Biotech's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.